Real-Life Analysis of Therapeutic Management and Its Correlation With the Dermatology Life Quality Index Score in 108 Patients With Pustular Psoriasis: An Italian Monocenter Study

Real-Life Analysis of Therapeutic Management and Its Correlation With the Dermatology Life Quality Index Score in 108 Patients With Pustular Psoriasis: An Italian Monocenter Study

Authors

  • Dario Buononato Unit of Dermatology, University of Campania “Luigi Vanvitelli”, Naples, Italy
  • Emanuele Scala Division of Dermatology and Venereology, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden ; Department of Dermatology and Venereology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
  • Pierfrancesco Benvenuto Università degli studi della campania Luigi Vanvitelli
  • Stefano Caccavale Università degli studi della campania Luigi Vanvitelli
  • Eugenia Veronica Di Brizzi Università degli studi della campania Luigi Vanvitelli
  • Roberta Di Caprio Università degli studi della campania Luigi Vanvitelli
  • Giuseppe Argenziano Università degli studi della campania Luigi Vanvitelli
  • Anna Balato Università degli studi della campania Luigi Vanvitelli

Keywords:

generalized pustular psoriasis, palmoplantar pustular pustulosis, DLQI, Psoriasis, Biological Therapy

Abstract

Introduction: Pustular psoriasis (PP) is a rare life-threatening skin disease with negatively impact on quality of life (QoL). Clinically, it may be systemic (generalized pustular psoriasis [GPP]) or localized on palms and soles (palmoplantar pustulosis [PPP]). It is not rare to observe plaque psoriasis associated with GPP.

Objective: We explored the therapies used for PP and their correlation with patient QoL scores, through a cross-sectional study using retrospective data from a monocentric database in the period 2017-2021.

Method: Patient characteristics were summarized using descriptive statistics and treatment predictors of QoL were identified by multiple regression analysis. Among 108 patients with PP, 57.4% had GPP + PSO whereas 42.6% had PPP. The therapeutic management is based on systemic conventional treatments and biological therapies in both GPP and PPP.

Results: GPP + PSO patients with an impaired QoL (DLQI≥10) were associated with biological therapy including certolizumab (OR=2.38), etanercept (OR=2.25), secukinumab (OR=2.03) or ustekinumab (OR=2.79) whereas, PPP patients were positively associated with secukinumab (OR=2.85) or apremilast (OR 4.28, 95%-CI 0.56-9.62).

Conclusion: Currently, systemic conventional therapy remains the therapeutic fulcrum of PP management. A great effect on QoL, especially for GPP+PSO, was assessed regardless the ongoing treatment and only newer biologic options were able to somehow positively impact.

References

Reich K, Augustin M, Gerdes S, et al. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion. J Dtsch Dermatol Ges. 2022;20:753-771. DOI: 10.1111/ddg.14764. PMID: 35674482.

Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey. Am J Clin Dermatol. 2022;23(Suppl 1):65-71. DOI: 10.1007/s40257-021-00663-y.

Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026. DOI: 10.1016/j.jaci.2018.06.038.

Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines. 2021;9(12):1746. DOI: 10.3390/biomedicines9121746.

Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021;47(4):118. DOI: 10.3892/ijmm.2021.4951.

Mössner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178(3):740-748. DOI: 10.1111/bjd.15867.

Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134(6):1755-1757. DOI: 10.1038/jid.2014.46.

Li L, You J, Fu X, et al. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. Br J Dermatol. 2019;180(2):425-426. DOI: 10.1111/bjd.17392.

Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021;11(6):1917-1929. DOI: 10.1007/s13555-021-00612-x.

Blair HA. Spesolimab: First Approval. Drugs. 2022;82(16):1681-1686. DOI: 10.1007/s40265-022-01801-4.

Morita A, Choon SE, Bachelez H, et al. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis. Dermatol Ther (Heidelb). 2023;13(2):347-359. DOI: 10.1007/s13555-022-00835-6.

Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021;22(9):4344. DOI: 10.3390/ijms22094344.

Khanskaya I, Pinkstaff J, Marino MH, Savall T, Li J, Londei M. A Phase 1 Study of ANB019, an Anti-IL-36 Receptor Monoclonal Antibody, in Healthy Volunteers. AnaptysBio. 2018. Disponibile su: https://www2.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf.

Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical Disease Measures in Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):39-50. DOI: 10.1007/s40257-021-00653-0.

Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145(3):546-553. DOI: 10.1046/j.1365-2133.2001.04411.x.

Scala E, Megna M, Amerio P, et al. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One. 2020;15(8):e0237267. DOI: doi:10.1371/journal.pone.0237267.

Tosukhowong T, Kiratikanon S, Wonglamsam P, et al. Epidemiology and clinical features of pustular psoriasis: A 15-year retrospective cohort. J Dermatol. 2021;48(12):1931-1935. DOI: 10.1111/1346-8138.16164.

Pfohler C, Muller CS, Vogt T. Psoriasis vulgaris and psoriasis pustulosa: epidemiology, quality of life, comorbidities and treatment. Curr Rheumatol Rev. 2013;9(1):2-7. DOI:10.2174/1573397111309010002.

Lu J, Wang Y, Li Y, Gong Y, Ding Y, Shi Y. Comparative study on the clinical efficacy and safety of acitretin and MTX in the treatment of pustular psoriasis by TLR7/MyD88/CXCL16 pathway. Appl Bionics Biomech. 2022;2022:9640326. DOI: Published 2022 Mar 18. doi:10.1155/2022/9640326.

Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969-980. DOI: 10.1080/14740338.2020.1785427.

Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889-899. DOI: 10.1111/bjd.18331.

Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266-1274. DOI:10.1016/j.jaad.2021.06.008.

Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651. DOI: 10.1111/jdv.14949.

Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349-358. DOI: 10.1007/s40257-016-0191-7.

Husson B, Barbe C, Hegazy S, et al; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330-2338. DOI: 10.1111/jdv.16265.

Ferrières L, Konstantinou MP, Bulai Livideanu C, et al. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. Clin Exp Dermatol. 2019;44(7):e230-e234. DOI: 10.1111/ced.13999.

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. J Dermatolog Treat. 2021;32(5):492-494. DOI:10.1080/09546634.2019.1682502.

Downloads

Published

2025-01-29

How to Cite

1.
Buononato D, Scala E, Benvenuto P, et al. Real-Life Analysis of Therapeutic Management and Its Correlation With the Dermatology Life Quality Index Score in 108 Patients With Pustular Psoriasis: An Italian Monocenter Study. Dermatol Pract Concept. 2025;15(1):4871. doi:10.5826/dpc.1501a4871

Share